Displaying 31 - 40 of 84 for Cancer - All
  • Immune Landscape of Thoracic Malignancies (H-35782)
    • The purpose of this clinical trial is to collect information on the types of immune cells found in and around the tumor site(s).
  • Improving Self-Management in Head and Neck Cancer (H-38984)
    • The purpose of this study is to evaluate a program that we have developed for head and neck cancer patients and their partners.
  • Locally Advanced Rectal Cancer, NRG-GI002 (H-41594)
    • This randomized phase II trial studies how well veliparib works with combination chemotherapy and radiation therapy in treating patients with rectal cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced). 
  • Longitudinal Testicular Cancer Database (H-19072)
    • The purpose of this study is to assess an outcome of patients suffering from germ cell testicular cancer.
  • Lung-MAP Study (H-35339)
    • This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid "Master Protocol" (S1400).
  • MABEL Study (H-35253)
    • In this study, we want to find out if we can use banked MABEL CTLs to treat HD or NHL, T/NK-lymphoproliferative disease and severe chronic active Epstein Barr Virus (CAEBV).
  • MAGENTA Study (H-40466)
    • This research study combines antibodies and T cells to fight a type of blood cancer called T-cell leukemia or lymphoma (lymph gland cancer).
  • MAGNIFY Study (H-35785)
    • The purpose of this study is to learn how well the combination of lenalidomide (an investigational drug) and a medicine called rituximab works in controlling some forms of non-Hodgkin lymphoma (NHL).
  • Malignant Pleural Mesothelioma Treatment Study (H-36460)
    • The primary objective of this study is to to determine the maximum tolerated dose of intrathoracic administration of pemetrexed when given in conjunction with cisplatin in patients with resectable MPM .
  • Meclizine for Hepatocellular Carcinoma (OPTIM) (H-40370)
    • The purpose of this study is to investigate if meclizine, a CAR inverse agonist, will have a beneficial therapeutic effect in patients with hepatocellular carcinoma.